IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	MAIL STOP AMENDMENT
Nicholas Bodor et al.) Group Art Unit: 1623
Application No.: 10/551,205	Examiner: JONATHAN S LAU
Filing Date: November 14, 2006	Confirmation No.: 4092
Title: ORAL FORMULATIONS OF CLADRIBINE	,)))

SIXTH INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

PTO-	Enclosed is a Sixth Information Enclosed is a Sixth Information Enclosed Enclosed		closure Statement (IDS) and accompanying form application.	
	No additional fee for submission of an IDS is required.			
\boxtimes	The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.			
	A statement under 37 C.F.R. § 1.17(p) is also enclosed.			
	A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.			
	Chargeto	Depos	sit Account No. 02-4800 for the fee due.	
\boxtimes	Charge <u>\$ 180</u> to credit card for the fee due. Form PTO-2038 is attached.			
\boxtimes	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.			
		Resp	ectfully submitted,	
		BUC	HANAN INGERSOLL AND ROONEY PC	
Date	<u>December 16, 2009</u>	Ву:	Mary Katherine Baumeister Registration No. 26254	

Customer No. 21839 703 836 6620